Although the EWSR1 fusions, most commonly EWS-FLI1, are known to drive cancer, there are currently no FDA-approved EWS-FLI1 inhibitors available, and targeting these fusions is a challenge [22]. The gene discussed is EWSR1; the disease is cancer.